WendyStockMD

Oncology • Chicago, IL

Hematologic Oncology

Professor of Medicine, University of Chicago Medicine

Join to view full profile

Dr. Stock is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stock's full profile

Already have an account?

Office
5841 S Maryland Ave
Chicago, IL 60637
Phone+1 888-824-0200

Fax+1 773-834-0778

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1989 - 1993
University of ChicagoResidency, Internal Medicine, 1985 - 1988
Rush Medical College of Rush University Medical CenterClass of 1985

Certifications & Licensure

IL State Medical License 1987 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Super Doctor SuperDoctors.com

Clinical Trials

Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia Start of enrollment: 1999 Jan 01
Completed
Phase 2
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia Start of enrollment: 1999 Apr 01
Active, not recruiting
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2002 Jul 01
Completed
Phase 1, Phase 2
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Start of enrollment: 2006 Jul 01
Terminated
Phase 2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
Active, not recruiting
Phase 2
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
Completed
Phase 2
Clofarabine Bone Marrow Cytoreduction Start of enrollment: 2007 Dec 01
Completed
Phase 2
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial Start of enrollment: 1998 Dec 15
Active, not recruiting
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
Completed
Phase 2
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia Start of enrollment: 2011 Jul 01
Completed
Early Phase 1
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Start of enrollment: 2012 Mar 01
Terminated
Phase 3
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2016 Mar 01
Terminated
Phase 1
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2017 Jul 14
Terminated
Phase 2
Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia Start of enrollment: 2023 Mar 01
Recruiting
Roles: Contact, Principal Investigator
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL Start of enrollment: 2017 Oct 30
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.
Marlise R Luskin, Jun Yin, Gerard Lozanski, Emily Curran, Gregory Malnassy
Cancer. 2025-02-15
2 citations
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker
Journal of Clinical Oncology. 2025-02-10
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
Marlise R Luskin, Mark A Murakami, Julia Keating, Yael Flamand, Eric S Winer
Blood. 2025-02-06

Journal Articles

Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia
Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature

Abstracts/Posters

Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelody...
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML
Wendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Adult Clinical Malignant Hematology
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
New Data and Paradigms in ALL: Insights and Applications
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Adult Clinical Malignant Hematology
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Rela...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with N...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Transitions From the Adult Perspective
60th American Society of Hematology Annual Meeting - 11/30/2018
Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosomeâ€positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Other

Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALL
Wendy Stock, MD, Blood
https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
UpToDate, Wolters Kluwer Health - 2013-04-03
Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALL
Wendy Stock, MD, Blood
https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
UpToDate, Wolters Kluwer Health - 2012-02-07
Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALL
Wendy Stock, MD, Blood
https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
UpToDate, Wolters Kluwer Health - 2012-09-10
Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALL
Wendy Stock, MD, Blood
https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
UpToDate, Wolters Kluwer Health - 2013-01-28
Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALL
Wendy Stock, MD, Blood
https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
UpToDate, Wolters Kluwer Health - 2012-03-28
Join now to see all

Press Mentions

Trial Suggests Expanded Role for Blinatumomab in Treating ALLJanuary 25th, 2023
Opportunity, Not Obligation: An Interview with Wendy Stock, MDDecember 1st, 2020
Chicago State’s Lance Irvin, a 2-Time Cancer Survivor, Isn’t Coaching in Person This Season Because of the Health Risks COVID-19 PresentsNovember 25th, 2020
Join now to see all